STOCK TITAN

Atea Pharmaceuticals (AVIR) director buys 6,100 shares of stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock on May 18, 2026 at a weighted average price of $4.1715 per share. Following this trade, she directly owns 92,145 shares of Atea Pharmaceuticals.

The shares were bought in multiple transactions at prices ranging from $4.14 to $4.19 per share. This Form 4/A amends a prior Form 4 only to correct the transaction date, which had been mistakenly reported as May 18, 2025 instead of May 18, 2026.

Positive

  • None.

Negative

  • None.
Insider Murphy Polly A.
Role null
Bought 6,100 shs ($25K)
Type Security Shares Price Value
Purchase Common Stock 6,100 $4.1715 $25K
Holdings After Transaction: Common Stock — 92,145 shares (Direct, null)
Footnotes (1)
  1. This Form 4/A has been filed solely to correct the date of the transaction reported in Column 2 of Table I of the Reporting Person's Form 4 filed on May 20, 2026, which was inadvertently noted as "May 18, 2025" instead of "May 18, 2026." The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Shares purchased 6,100 shares Open-market purchase on May 18, 2026
Weighted average price $4.1715 per share Price paid for 6,100 shares
Post-transaction holdings 92,145 shares Common Stock directly owned after purchase
Trade price range $4.14–$4.19 per share Range of individual trade prices within purchase
Net shares bought 6,100 shares Net buy direction in transaction summary
Form 4/A regulatory
"This Form 4/A has been filed solely to correct the date of the transaction"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
transaction code "P" regulatory
"transaction_code_description: "Purchase in open market or private transaction""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Murphy Polly A.

(Last)(First)(Middle)
225 FRANKLIN STREET
SUITE 2100

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
05/20/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026(1)P6,100A$4.1715(2)92,145D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This Form 4/A has been filed solely to correct the date of the transaction reported in Column 2 of Table I of the Reporting Person's Form 4 filed on May 20, 2026, which was inadvertently noted as "May 18, 2025" instead of "May 18, 2026."
2. The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Andrea Corcoran, as Attorney-in-Fact for Polly A. Murphy05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Atea Pharmaceuticals (AVIR) report for Polly A. Murphy?

Atea Pharmaceuticals director Polly A. Murphy reported buying 6,100 shares of Common Stock in an open-market transaction on May 18, 2026, at a weighted average price of $4.1715 per share, increasing her direct ownership to 92,145 shares.

Why was this Atea Pharmaceuticals (AVIR) Form 4/A filed as an amendment?

The Form 4/A was filed solely to correct the transaction date previously reported. The original Form 4 listed the purchase date as May 18, 2025, but the amendment clarifies the correct date was May 18, 2026 for the same 6,100-share transaction.

What price range did Polly A. Murphy pay for Atea Pharmaceuticals (AVIR) shares?

The director’s purchase used a weighted average price of $4.1715 per share. According to the filing, individual trades occurred in multiple transactions at prices ranging from $4.14 to $4.19 per share of Atea Pharmaceuticals Common Stock.

How many Atea Pharmaceuticals (AVIR) shares does Polly A. Murphy own after the transaction?

After purchasing 6,100 shares, Polly A. Murphy directly owns 92,145 shares of Atea Pharmaceuticals Common Stock. This total reflects her holdings immediately following the reported May 18, 2026 open-market transaction detailed in the Form 4/A.

What type of transaction did Polly A. Murphy execute in Atea Pharmaceuticals (AVIR) stock?

The filing describes the trade as an open-market purchase of Atea Pharmaceuticals Common Stock. The transaction is coded as a “P” purchase, indicating shares were acquired in the market rather than through options exercises, gifts, or other non-market mechanisms.